PART and SNAP.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

54 citing papers in PubMed.

1. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.Human brain mapping · 2018
   Trial
2. Evidence for different seeding activities of misfolded tau in classical and rapidly progressive Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
   Article
3. Alzheimer mimicry: LATE and PART.Journal of neural transmission (Vienna, Austria : 1996) · 2025
   Review
4. Distinct Characteristics of Suspected Non-Alzheimer Pathophysiology in Relation to Cognitive Status and Cerebrovascular Burden.Clinical nuclear medicine · 2025
   Article
5. Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease.Alzheimer's research & therapy · 2024
   Article
6. Investigating the feasibility ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Observational
7. Prevalence and clinicopathological features of primary age-related tauopathy (PART): A large forensic autopsy study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Article
8. Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
   Article
9. Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer's disease (AD) mimickers.European journal of nuclear medicine and molecular imaging · 2024
   Article
10. Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.Brain : a journal of neurology · 2022
    Observational
11. MulticenterBiomolecules · 2022
    Article
12. Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer's Disease Patients-Relationship toBrain sciences · 2021
    Article
13. Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.Acta neuropathologica communications · 2021
    Article
14. Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology.Alzheimer's research & therapy · 2021
    Article
15. Molecular Imaging Approaches in Dementia.Radiology · 2021
    Review
16. PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research.Frontiers in aging neuroscience · 2021
    Review
17. Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease.International journal of molecular sciences · 2020
    Review
18. Tau PET imaging in neurodegenerative tauopathies-still a challenge.Molecular psychiatry · 2019
    Review
19. Associations between quantitative [Alzheimer's research & therapy · 2019
    Article
20. Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury.European journal of nuclear medicine and molecular imaging · 2019
    Article

Corrections and comments

• Comment on
  Primary age-related tauopathy (PART): a common pathology associated with human aging.2014

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as